SCHEMBL5529930

SCHEMBL5529930

C#Cc1ccc(NC(=O)c2cc(OC)ccc2N(C=O)c2ccc(C=NN(C)CCC)cc2F)nc1

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
F10 P00742 3/20 0.35
KCNH2 Q12809 3/20 0.35
NPC1 O15118 4/20 0.34
RAB9A P51151 4/20 0.34
TP53 P04637 3/20 0.34
MITF O75030 1/20 0.34
GAA P10253 1/20 0.34
F2 P00734 1/20 0.33
FGFR4 P22455 1/20 0.33
KMT2A Q03164 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C9 P11712 1/20 0.31
MEN1 O00255 1/20 0.30
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5531803 0.94 F10 (0.36) F10KCNH2NPC1RAB9ATP53
SCHEMBL5533803 0.91 F10 (0.38) F10KCNH2NPC1RAB9ATP53
SCHEMBL5532157 0.86 F10 (0.43) F10KCNH2
SCHEMBL5537319 0.86 F10 (0.38) F10KCNH2F2
SCHEMBL5534115 0.85 NPC1 (0.36) F10KCNH2NPC1RAB9ATP53
SCHEMBL5532034 0.82 KDM4E (0.34) F10KMT2AMEN1POLB
SCHEMBL5533499 0.82 F10 (0.38) F10KCNH2NPC1RAB9ASMN1; SMN2
SCHEMBL5531693 0.82 FGFR4 (0.38) F10KCNH2NPC1RAB9ATP53
SCHEMBL5531606 0.81 F10 (0.47) F10KCNH2NPC1RAB9AFGFR4
SCHEMBL5535739 0.81 F10 (0.46) F10KCNH2FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1373194-B1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARM INC (US) 2007-08-01 EP claimed
EP-1373194-A1 BENZAMIDE INHIBITORS OF FACTOR Xa Millennium Pharmaceuticals, Inc. (US) 2004-01-02 EP claimed
WO-2002079145-A1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-10-10 WO claimed
US-7312235-B2 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-12-25 US disclosed
EP-1373194-A1 BENZAMIDE INHIBITORS OF FACTOR Xa Millennium Pharmaceuticals, Inc. (US) 2004-01-02 EP disclosed
US-20030069250-A1 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. 2003-04-10 US disclosed
WO-2002079145-A1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069250-A1 Benzamide inhibitors of factor Xa SERPINC1, TFPI, F12 F10 10/4885KCNH2 1203/4885NPC1 2635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.